Traws Pharma receives Nasdaq delisting notice for stockholders' deficit of $105.5M

Traws Pharma, Inc.

Received Nasdaq letter on Aug 21, 2024 for non-compliance with minimum $2.5M stockholders' equity.
Reported stockholders' deficit of $105.5M as of June 30, 2024, below the required minimum.
Must submit a compliance plan by Oct 7, 2024; extension possible to Feb 18, 2025.
No immediate effect on listing, but failure to regain compliance may lead to delisting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.